$AVM Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in AMAG PHARMACEUTICALS, INC..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in AMAG PHARMACEUTICALS, INC.. Get notifications about new insider transactions in AMAG PHARMACEUTICALS, INC. for free.
Page: < prev 1 2 3 4 5 6 7 ... 11 next >
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| May 02 2018 | AVM | AMAG PHARMACEUTICA ... | Butcher James Alan | EVP, Chief Business ... | Option Exercise | A | 20.55 | 62,393 | 1,282,176 | 62,393 | |
| May 02 2018 | AVM | AMAG PHARMACEUTICA ... | Butcher James Alan | EVP, Chief Business ... | Grant | A | 0.00 | 28,418 | 0 | 28,418 | 0 to 28.4 K |
| Mar 06 2018 | AVM | AMAG PHARMACEUTICA ... | Vittiglio Joseph | EVP, General Counse ... | Option Exercise | A | 21.00 | 20,000 | 420,000 | 20,000 | |
| Mar 06 2018 | AVM | AMAG PHARMACEUTICA ... | Vittiglio Joseph | EVP, General Counse ... | Sell | S | 20.80 | 770 | 16,016 | 52,854 | 53.6 K to 52.9 K (-1.44 %) |
| Mar 06 2018 | AVM | AMAG PHARMACEUTICA ... | Vittiglio Joseph | EVP, General Counse ... | Payment of Exercise | F | 21.00 | 1,011 | 21,231 | 53,624 | 54.6 K to 53.6 K (-1.85 %) |
| Mar 06 2018 | AVM | AMAG PHARMACEUTICA ... | Vittiglio Joseph | EVP, General Counse ... | Grant | A | 0.00 | 10,000 | 0 | 54,635 | 44.6 K to 54.6 K (+22.40 %) |
| Mar 06 2018 | AVM | AMAG PHARMACEUTICA ... | Vittiglio Joseph | EVP, General Counse ... | Grant | A | 0.00 | 12,000 | 0 | 44,635 | 32.6 K to 44.6 K (+36.77 %) |
| Mar 06 2018 | AVM | AMAG PHARMACEUTICA ... | Vittiglio Joseph | EVP, General Counse ... | Payment of Exercise | F | 19.65 | 869 | 17,076 | 32,635 | 33.5 K to 32.6 K (-2.59 %) |
| Mar 06 2018 | AVM | AMAG PHARMACEUTICA ... | HEIDEN WILLIAM K | President & CEO | Option Exercise | A | 21.00 | 100,000 | 2,100,000 | 100,000 | |
| Mar 06 2018 | AVM | AMAG PHARMACEUTICA ... | HEIDEN WILLIAM K | President & CEO | Payment of Exercise | F | 21.00 | 10,546 | 221,466 | 353,015 | 363.6 K to 353 K (-2.90 %) |
| Mar 06 2018 | AVM | AMAG PHARMACEUTICA ... | HEIDEN WILLIAM K | President & CEO | Grant | A | 0.00 | 45,500 | 0 | 363,561 | 318.1 K to 363.6 K (+14.31 %) |
| Mar 06 2018 | AVM | AMAG PHARMACEUTICA ... | HEIDEN WILLIAM K | President & CEO | Grant | A | 0.00 | 45,500 | 0 | 318,061 | 272.6 K to 318.1 K (+16.69 %) |
| Mar 06 2018 | AVM | AMAG PHARMACEUTICA ... | Krop Julie | EVP, CMO | Option Exercise | A | 21.00 | 22,000 | 462,000 | 22,000 | |
| Mar 06 2018 | AVM | AMAG PHARMACEUTICA ... | Krop Julie | EVP, CMO | Payment of Exercise | F | 21.00 | 1,700 | 35,700 | 51,636 | 53.3 K to 51.6 K (-3.19 %) |
| Mar 06 2018 | AVM | AMAG PHARMACEUTICA ... | Krop Julie | EVP, CMO | Grant | A | 0.00 | 12,000 | 0 | 53,336 | 41.3 K to 53.3 K (+29.03 %) |
| Mar 06 2018 | AVM | AMAG PHARMACEUTICA ... | Krop Julie | EVP, CMO | Grant | A | 0.00 | 13,000 | 0 | 41,336 | 28.3 K to 41.3 K (+45.88 %) |
| Mar 06 2018 | AVM | AMAG PHARMACEUTICA ... | Grund Nicholas | Chief Commercial Of ... | Option Exercise | A | 21.00 | 24,000 | 504,000 | 24,000 | |
| Mar 06 2018 | AVM | AMAG PHARMACEUTICA ... | Grund Nicholas | Chief Commercial Of ... | Payment of Exercise | F | 21.00 | 4,193 | 88,053 | 66,324 | 70.5 K to 66.3 K (-5.95 %) |
| Mar 06 2018 | AVM | AMAG PHARMACEUTICA ... | Grund Nicholas | Chief Commercial Of ... | Grant | A | 0.00 | 12,000 | 0 | 70,517 | 58.5 K to 70.5 K (+20.51 %) |
| Mar 06 2018 | AVM | AMAG PHARMACEUTICA ... | Grund Nicholas | Chief Commercial Of ... | Grant | A | 0.00 | 10,000 | 0 | 58,517 | 48.5 K to 58.5 K (+20.61 %) |
| Mar 06 2018 | AVM | AMAG PHARMACEUTICA ... | Myles Edward H | Chief Financial Off ... | Option Exercise | A | 21.00 | 24,000 | 504,000 | 24,000 | |
| Mar 06 2018 | AVM | AMAG PHARMACEUTICA ... | Myles Edward H | Chief Financial Off ... | Payment of Exercise | F | 21.00 | 854 | 17,934 | 53,294 | 54.1 K to 53.3 K (-1.58 %) |
| Mar 06 2018 | AVM | AMAG PHARMACEUTICA ... | Myles Edward H | Chief Financial Off ... | Grant | A | 0.00 | 10,000 | 0 | 54,148 | 44.1 K to 54.1 K (+22.65 %) |
| Mar 06 2018 | AVM | AMAG PHARMACEUTICA ... | Myles Edward H | Chief Financial Off ... | Grant | A | 0.00 | 10,000 | 0 | 44,148 | 34.1 K to 44.1 K (+29.28 %) |
| Mar 06 2018 | AVM | AMAG PHARMACEUTICA ... | Bolgiano Elizabeth Scott | Chief Human Resourc ... | Option Exercise | A | 21.00 | 20,000 | 420,000 | 20,000 | |
| Mar 06 2018 | AVM | AMAG PHARMACEUTICA ... | Bolgiano Elizabeth Scott | Chief Human Resourc ... | Payment of Exercise | F | 21.00 | 3,549 | 74,529 | 56,918 | 60.5 K to 56.9 K (-5.87 %) |
| Mar 06 2018 | AVM | AMAG PHARMACEUTICA ... | Bolgiano Elizabeth Scott | Chief Human Resourc ... | Grant | A | 0.00 | 9,000 | 0 | 60,467 | 51.5 K to 60.5 K (+17.49 %) |
| Mar 06 2018 | AVM | AMAG PHARMACEUTICA ... | Bolgiano Elizabeth Scott | Chief Human Resourc ... | Grant | A | 0.00 | 9,000 | 0 | 51,467 | 42.5 K to 51.5 K (+21.19 %) |
| Aug 30 2017 | AVM | AMAG PHARMACEUTICA ... | Vittiglio Joseph | SVP, General Counse ... | Sell | S | 16.75 | 1,250 | 20,938 | 33,504 | 34.8 K to 33.5 K (-3.60 %) |
| Aug 28 2017 | AVM | AMAG PHARMACEUTICA ... | Vittiglio Joseph | SVP, General Counse ... | Payment of Exercise | F | 17.50 | 1,633 | 28,578 | 34,754 | 36.4 K to 34.8 K (-4.49 %) |
| Jul 14 2017 | AVM | AMAG PHARMACEUTICA ... | Krop Julie | SVP Clinical & Regu ... | Sell | S | 20.00 | 4,938 | 98,760 | 28,336 | 33.3 K to 28.3 K (-14.84 %) |
| Jun 05 2017 | AVM | AMAG PHARMACEUTICA ... | Krop Julie | SVP Clinical & Regu ... | Payment of Exercise | F | 17.90 | 2,395 | 42,871 | 33,274 | 35.7 K to 33.3 K (-6.71 %) |
| Jun 05 2017 | AVM | AMAG PHARMACEUTICA ... | Krop Julie | SVP Clinical & Regu ... | Payment of Exercise | F | 22.85 | 1,108 | 25,318 | 35,669 | 36.8 K to 35.7 K (-3.01 %) |
| May 22 2017 | AVM | AMAG PHARMACEUTICA ... | SULAT JAMES R | Director | Option Exercise | A | 19.25 | 10,110 | 194,618 | 10,110 | |
| May 22 2017 | AVM | AMAG PHARMACEUTICA ... | SULAT JAMES R | Director | Grant | A | 0.00 | 4,545 | 0 | 13,127 | 8.6 K to 13.1 K (+52.96 %) |
| May 22 2017 | AVM | AMAG PHARMACEUTICA ... | Deptula Barbara | Director | Option Exercise | A | 19.25 | 10,110 | 194,618 | 10,110 | |
| May 22 2017 | AVM | AMAG PHARMACEUTICA ... | Deptula Barbara | Director | Grant | A | 0.00 | 4,545 | 0 | 14,660 | 10.1 K to 14.7 K (+44.93 %) |
| May 22 2017 | AVM | AMAG PHARMACEUTICA ... | Fallon John A. | Director | Option Exercise | A | 19.25 | 10,110 | 194,618 | 10,110 | |
| May 22 2017 | AVM | AMAG PHARMACEUTICA ... | Fallon John A. | Director | Grant | A | 0.00 | 4,545 | 0 | 15,399 | 10.9 K to 15.4 K (+41.87 %) |
| May 22 2017 | AVM | AMAG PHARMACEUTICA ... | KELLEY BRIAN P | Director | Option Exercise | A | 19.25 | 10,110 | 194,618 | 10,110 | |
| May 22 2017 | AVM | AMAG PHARMACEUTICA ... | KELLEY BRIAN P | Director | Grant | A | 0.00 | 4,545 | 0 | 5,571 | 1 K to 5.6 K (+442.98 %) |
| May 22 2017 | AVM | AMAG PHARMACEUTICA ... | Russell Lesley | Director | Option Exercise | A | 19.25 | 10,110 | 194,618 | 10,110 | |
| May 22 2017 | AVM | AMAG PHARMACEUTICA ... | Russell Lesley | Director | Grant | A | 0.00 | 4,545 | 0 | 21,335 | 16.8 K to 21.3 K (+27.07 %) |
| May 22 2017 | AVM | AMAG PHARMACEUTICA ... | SANTINI GINO | Director | Option Exercise | A | 19.25 | 10,110 | 194,618 | 10,110 | |
| May 22 2017 | AVM | AMAG PHARMACEUTICA ... | SANTINI GINO | Director | Grant | A | 0.00 | 4,545 | 0 | 19,510 | 15 K to 19.5 K (+30.37 %) |
| May 22 2017 | AVM | AMAG PHARMACEUTICA ... | SCOON DAVEY | Director | Option Exercise | A | 19.25 | 10,110 | 194,618 | 10,110 | |
| May 22 2017 | AVM | AMAG PHARMACEUTICA ... | SCOON DAVEY | Director | Grant | A | 0.00 | 4,545 | 0 | 21,935 | 17.4 K to 21.9 K (+26.14 %) |
| May 22 2017 | AVM | AMAG PHARMACEUTICA ... | PEREZ ROBERT J | Director | Option Exercise | A | 19.25 | 10,110 | 194,618 | 10,110 | |
| May 22 2017 | AVM | AMAG PHARMACEUTICA ... | PEREZ ROBERT J | Director | Grant | A | 0.00 | 4,545 | 0 | 17,535 | 13 K to 17.5 K (+34.99 %) |
| May 10 2017 | AVM | AMAG PHARMACEUTICA ... | HEIDEN WILLIAM K | President & CEO | Payment of Exercise | F | 18.55 | 19,085 | 354,027 | 272,561 | 291.6 K to 272.6 K (-6.54 %) |
| May 10 2017 | AVM | AMAG PHARMACEUTICA ... | Myles Edward H | Chief Financial Off ... | Payment of Exercise | F | 18.55 | 2,177 | 40,383 | 32,823 | 35 K to 32.8 K (-6.22 %) |
| May 10 2017 | AVM | AMAG PHARMACEUTICA ... | Vittiglio Joseph | SVP, General Counse ... | Payment of Exercise | F | 18.55 | 980 | 18,179 | 36,387 | 37.4 K to 36.4 K (-2.62 %) |
| May 10 2017 | AVM | AMAG PHARMACEUTICA ... | Grund Nicholas | Chief Commercial Of ... | Payment of Exercise | F | 18.55 | 3,483 | 64,610 | 48,517 | 52 K to 48.5 K (-6.70 %) |
| May 02 2017 | AVM | AMAG PHARMACEUTICA ... | Krop Julie | SVP Clinical & Regu ... | Sell | S | 24.45 | 1,891 | 46,235 | 36,777 | 38.7 K to 36.8 K (-4.89 %) |
| Feb 27 2017 | AVM | AMAG PHARMACEUTICA ... | HEIDEN WILLIAM K | CEO | Option Exercise | A | 23.75 | 65,000 | 1,543,750 | 65,000 | |
| Feb 27 2017 | AVM | AMAG PHARMACEUTICA ... | HEIDEN WILLIAM K | CEO | Grant | A | 0.00 | 55,000 | 0 | 291,646 | 236.6 K to 291.6 K (+23.24 %) |
| Feb 27 2017 | AVM | AMAG PHARMACEUTICA ... | HEIDEN WILLIAM K | CEO | Grant | A | 0.00 | 30,000 | 0 | 236,646 | 206.6 K to 236.6 K (+14.52 %) |
| Feb 27 2017 | AVM | AMAG PHARMACEUTICA ... | Vittiglio Joseph | SVP, General Counse ... | Option Exercise | A | 23.75 | 20,000 | 475,000 | 20,000 | |
| Feb 27 2017 | AVM | AMAG PHARMACEUTICA ... | Vittiglio Joseph | SVP, General Counse ... | Grant | A | 0.00 | 7,500 | 0 | 37,367 | 29.9 K to 37.4 K (+25.11 %) |
| Feb 27 2017 | AVM | AMAG PHARMACEUTICA ... | Vittiglio Joseph | SVP, General Counse ... | Grant | A | 0.00 | 7,500 | 0 | 29,867 | 22.4 K to 29.9 K (+33.53 %) |
| Feb 27 2017 | AVM | AMAG PHARMACEUTICA ... | THOMAS FRANK E | President & COO | Option Exercise | A | 23.75 | 30,000 | 712,500 | 30,000 | |
| Feb 27 2017 | AVM | AMAG PHARMACEUTICA ... | THOMAS FRANK E | President & COO | Grant | A | 0.00 | 12,000 | 0 | 138,195 | 126.2 K to 138.2 K (+9.51 %) |
| Feb 27 2017 | AVM | AMAG PHARMACEUTICA ... | THOMAS FRANK E | President & COO | Grant | A | 0.00 | 12,000 | 0 | 126,195 | 114.2 K to 126.2 K (+10.51 %) |
| Feb 27 2017 | AVM | AMAG PHARMACEUTICA ... | Grund Nicholas | Chief Commercial Of ... | Option Exercise | A | 23.75 | 25,000 | 593,750 | 25,000 | |
| Feb 27 2017 | AVM | AMAG PHARMACEUTICA ... | Grund Nicholas | Chief Commercial Of ... | Grant | A | 0.00 | 10,000 | 0 | 52,000 | 42 K to 52 K (+23.81 %) |
| Feb 27 2017 | AVM | AMAG PHARMACEUTICA ... | Grund Nicholas | Chief Commercial Of ... | Grant | A | 0.00 | 10,000 | 0 | 42,000 | 32 K to 42 K (+31.25 %) |
| Feb 27 2017 | AVM | AMAG PHARMACEUTICA ... | Krop Julie | SVP Clinical & Regu ... | Option Exercise | A | 23.75 | 20,000 | 475,000 | 20,000 | |
| Feb 27 2017 | AVM | AMAG PHARMACEUTICA ... | Krop Julie | SVP Clinical & Regu ... | Grant | A | 0.00 | 7,500 | 0 | 38,668 | 31.2 K to 38.7 K (+24.06 %) |
| Feb 27 2017 | AVM | AMAG PHARMACEUTICA ... | Krop Julie | SVP Clinical & Regu ... | Grant | A | 0.00 | 7,500 | 0 | 31,168 | 23.7 K to 31.2 K (+31.69 %) |
| Feb 27 2017 | AVM | AMAG PHARMACEUTICA ... | Myles Edward H | Chief Financial Off ... | Option Exercise | A | 23.75 | 20,000 | 475,000 | 20,000 | |
| Feb 27 2017 | AVM | AMAG PHARMACEUTICA ... | Myles Edward H | Chief Financial Off ... | Grant | A | 0.00 | 7,500 | 0 | 35,000 | 27.5 K to 35 K (+27.27 %) |
| Feb 27 2017 | AVM | AMAG PHARMACEUTICA ... | Myles Edward H | Chief Financial Off ... | Grant | A | 0.00 | 7,500 | 0 | 27,500 | 20 K to 27.5 K (+37.50 %) |
| Dec 22 2016 | AVM | AMAG PHARMACEUTICA ... | KELLEY BRIAN P | Director | Option Exercise | A | 35.50 | 2,739 | 97,235 | 2,739 | |
| Dec 22 2016 | AVM | AMAG PHARMACEUTICA ... | KELLEY BRIAN P | Director | Option Exercise | A | 35.50 | 6,000 | 213,000 | 6,000 | |
| Dec 22 2016 | AVM | AMAG PHARMACEUTICA ... | KELLEY BRIAN P | Director | Grant | A | 0.00 | 1,026 | 0 | 1,026 | 0 to 1 K |
| Oct 20 2016 | AVM | AMAG PHARMACEUTICA ... | Krop Julie | SVP Clinical & Regu ... | Sell | S | 24.80 | 4,938 | 122,462 | 23,668 | 28.6 K to 23.7 K (-17.26 %) |
| Aug 25 2016 | AVM | AMAG PHARMACEUTICA ... | Vittiglio Joseph | SVP, General Counse ... | Payment of Exercise | F | 24.85 | 1,633 | 40,580 | 22,367 | 24 K to 22.4 K (-6.80 %) |
| Jun 02 2016 | AVM | AMAG PHARMACEUTICA ... | Krop Julie | SVP Clinical & Regu ... | Payment of Exercise | F | 22.13 | 2,394 | 52,979 | 28,606 | 31 K to 28.6 K (-7.72 %) |
| May 23 2016 | AVM | AMAG PHARMACEUTICA ... | Fallon John A. | Director | Option Exercise | A | 18.35 | 12,787 | 234,641 | 12,787 | |
| May 23 2016 | AVM | AMAG PHARMACEUTICA ... | Fallon John A. | Director | Grant | A | 0.00 | 4,768 | 0 | 10,854 | 6.1 K to 10.9 K (+78.34 %) |
| May 23 2016 | AVM | AMAG PHARMACEUTICA ... | PEREZ ROBERT J | Director | Option Exercise | A | 18.35 | 12,787 | 234,641 | 12,787 | |
| May 23 2016 | AVM | AMAG PHARMACEUTICA ... | PEREZ ROBERT J | Director | Grant | A | 0.00 | 4,768 | 0 | 12,990 | 8.2 K to 13 K (+57.99 %) |
| May 23 2016 | AVM | AMAG PHARMACEUTICA ... | Deptula Barbara | Director | Option Exercise | A | 18.35 | 12,787 | 234,641 | 12,787 | |
| May 23 2016 | AVM | AMAG PHARMACEUTICA ... | Deptula Barbara | Director | Grant | A | 0.00 | 4,768 | 0 | 10,115 | 5.3 K to 10.1 K (+89.17 %) |
| May 23 2016 | AVM | AMAG PHARMACEUTICA ... | Russell Lesley | Director | Option Exercise | A | 18.35 | 12,787 | 234,641 | 12,787 | |
| May 23 2016 | AVM | AMAG PHARMACEUTICA ... | Russell Lesley | Director | Grant | A | 0.00 | 4,768 | 0 | 16,790 | 12 K to 16.8 K (+39.66 %) |
| May 23 2016 | AVM | AMAG PHARMACEUTICA ... | SCOON DAVEY | Director | Option Exercise | A | 18.35 | 12,787 | 234,641 | 12,787 | |
| May 23 2016 | AVM | AMAG PHARMACEUTICA ... | SCOON DAVEY | Director | Grant | A | 0.00 | 4,768 | 0 | 17,390 | 12.6 K to 17.4 K (+37.78 %) |
| May 23 2016 | AVM | AMAG PHARMACEUTICA ... | SANTINI GINO | Director | Option Exercise | A | 18.35 | 12,787 | 234,641 | 12,787 | |
| May 23 2016 | AVM | AMAG PHARMACEUTICA ... | SANTINI GINO | Director | Grant | A | 0.00 | 4,768 | 0 | 14,965 | 10.2 K to 15 K (+46.76 %) |
| May 23 2016 | AVM | AMAG PHARMACEUTICA ... | SULAT JAMES R | Director | Option Exercise | A | 18.35 | 12,787 | 234,641 | 12,787 | |
| May 23 2016 | AVM | AMAG PHARMACEUTICA ... | SULAT JAMES R | Director | Grant | A | 0.00 | 4,768 | 0 | 8,582 | 3.8 K to 8.6 K (+125.01 %) |
| May 17 2016 | AVM | AMAG PHARMACEUTICA ... | HEIDEN WILLIAM K | CEO | Payment of Exercise | F | 18.27 | 11,812 | 215,805 | 206,646 | 194.8 K to 206.6 K (+6.06 %) |
| Mar 02 2016 | AVM | AMAG PHARMACEUTICA ... | Krop Julie | SVP Clinical & Regu ... | Option Exercise | A | 25.18 | 22,500 | 566,550 | 22,500 | |
| Mar 02 2016 | AVM | AMAG PHARMACEUTICA ... | Krop Julie | SVP Clinical & Regu ... | Grant | A | 0.00 | 9,000 | 0 | 31,000 | 22 K to 31 K (+40.91 %) |
| Mar 02 2016 | AVM | AMAG PHARMACEUTICA ... | Vittiglio Joseph | SVP, General Counse ... | Option Exercise | A | 25.18 | 20,000 | 503,600 | 20,000 | |
| Mar 02 2016 | AVM | AMAG PHARMACEUTICA ... | Vittiglio Joseph | SVP, General Counse ... | Grant | A | 0.00 | 9,000 | 0 | 24,000 | 15 K to 24 K (+60.00 %) |
| Mar 01 2016 | AVM | AMAG PHARMACEUTICA ... | THOMAS FRANK E | President & COO | Option Exercise | A | 25.18 | 40,000 | 1,007,200 | 40,000 | |
| Mar 01 2016 | AVM | AMAG PHARMACEUTICA ... | THOMAS FRANK E | President & COO | Grant | A | 0.00 | 17,000 | 0 | 114,195 | 97.2 K to 114.2 K (+17.49 %) |
| Mar 01 2016 | AVM | AMAG PHARMACEUTICA ... | THOMAS FRANK E | President & COO | Payment of Exercise | F | 26.28 | 515 | 13,534 | 97,195 | 97.7 K to 97.2 K (-0.53 %) |
| Mar 01 2016 | AVM | AMAG PHARMACEUTICA ... | THOMAS FRANK E | President & COO | Payment of Exercise | F | 27.01 | 458 | 12,371 | 97,710 | 98.2 K to 97.7 K (-0.47 %) |
| Mar 01 2016 | AVM | AMAG PHARMACEUTICA ... | THOMAS FRANK E | President & COO | Payment of Exercise | F | 27.01 | 1,361 | 36,761 | 98,168 | 99.5 K to 98.2 K (-1.37 %) |
| Mar 01 2016 | AVM | AMAG PHARMACEUTICA ... | THOMAS FRANK E | President & COO | Payment of Exercise | F | 27.01 | 7,417 | 200,333 | 99,529 | 106.9 K to 99.5 K (-6.94 %) |
| Mar 01 2016 | AVM | AMAG PHARMACEUTICA ... | HEIDEN WILLIAM K | CEO | Option Exercise | A | 25.18 | 85,000 | 2,140,300 | 85,000 | |
| Mar 01 2016 | AVM | AMAG PHARMACEUTICA ... | HEIDEN WILLIAM K | CEO | Grant | A | 0.00 | 36,000 | 0 | 218,458 | 182.5 K to 218.5 K (+19.73 %) |
| Mar 01 2016 | AVM | AMAG PHARMACEUTICA ... | HEIDEN WILLIAM K | CEO | Payment of Exercise | F | 26.28 | 1,701 | 44,702 | 182,458 | 184.2 K to 182.5 K (-0.92 %) |
| Mar 01 2016 | AVM | AMAG PHARMACEUTICA ... | HEIDEN WILLIAM K | CEO | Payment of Exercise | F | 27.01 | 1,843 | 49,779 | 184,159 | 186 K to 184.2 K (-0.99 %) |
| Mar 01 2016 | AVM | AMAG PHARMACEUTICA ... | HEIDEN WILLIAM K | CEO | Payment of Exercise | F | 27.01 | 4,070 | 109,931 | 186,002 | 190.1 K to 186 K (-2.14 %) |
| Mar 01 2016 | AVM | AMAG PHARMACEUTICA ... | HEIDEN WILLIAM K | CEO | Payment of Exercise | F | 27.01 | 10,649 | 287,629 | 190,072 | 200.7 K to 190.1 K (-5.31 %) |
| Apr 11 2016 | AVM | AMAG PHARMACEUTICA ... | Myles Edward H | Chief Financial Off ... | Option Exercise | A | 24.58 | 35,000 | 860,300 | 35,000 | |
| Apr 11 2016 | AVM | AMAG PHARMACEUTICA ... | Myles Edward H | Chief Financial Off ... | Grant | A | 0.00 | 20,000 | 0 | 20,000 | 0 to 20 K |
| Jan 05 2016 | AVM | AMAG PHARMACEUTICA ... | Grund Nicholas | Chief Commercial Of ... | Option Exercise | A | 28.58 | 45,000 | 1,286,100 | 45,000 | |
| Jan 05 2016 | AVM | AMAG PHARMACEUTICA ... | Grund Nicholas | Chief Commercial Of ... | Grant | A | 0.00 | 32,000 | 0 | 32,000 | 0 to 32 K |
| Dec 04 2015 | AVM | AMAG PHARMACEUTICA ... | Wilson Kenneth H | SVP, Sales and Mark ... | Payment of Exercise | F | 27.82 | 1,613 | 44,874 | 23,387 | 25 K to 23.4 K (-6.45 %) |
| Nov 10 2015 | AVM | AMAG PHARMACEUTICA ... | Fallon John A. | Director | Buy | P | 31.20 | 3,230 | 100,776 | 6,086 | 2.9 K to 6.1 K (+113.10 %) |
| Oct 02 2015 | AVM | AMAG PHARMACEUTICA ... | HEIDEN WILLIAM K | CEO | Sell | S | 39.69 | 2,000 | 79,380 | 200,721 | 202.7 K to 200.7 K (-0.99 %) |
| Sep 02 2015 | AVM | AMAG PHARMACEUTICA ... | Crouse Geoffrey | EVP | Option Exercise | A | 62.54 | 37,500 | 2,345,250 | 37,500 | |
| Sep 02 2015 | AVM | AMAG PHARMACEUTICA ... | Crouse Geoffrey | EVP | Grant | A | 0.00 | 18,750 | 0 | 18,750 | 0 to 18.8 K |
| Sep 02 2015 | AVM | AMAG PHARMACEUTICA ... | HEIDEN WILLIAM K | CEO | Sell | S | 61.19 | 2,000 | 122,380 | 202,721 | 204.7 K to 202.7 K (-0.98 %) |
| Aug 25 2015 | AVM | AMAG PHARMACEUTICA ... | Vittiglio Joseph | SVP, General Counse ... | Option Exercise | A | 57.60 | 30,000 | 1,728,000 | 30,000 | |
| Aug 25 2015 | AVM | AMAG PHARMACEUTICA ... | Vittiglio Joseph | SVP, General Counse ... | Grant | A | 0.00 | 15,000 | 0 | 15,000 | 0 to 15 K |
| Aug 21 2015 | AVM | AMAG PHARMACEUTICA ... | THOMAS FRANK E | President & COO | Payment of Exercise | F | 61.71 | 2,363 | 145,821 | 106,946 | 109.3 K to 106.9 K (-2.16 %) |
| Aug 07 2015 | AVM | AMAG PHARMACEUTICA ... | THOMAS FRANK E | President & COO | Option Exercise | M | 14.91 | 15,000 | 223,650 | 45,000 | |
| Aug 07 2015 | AVM | AMAG PHARMACEUTICA ... | THOMAS FRANK E | President & COO | Sell | S | 66.85 | 15,000 | 1,002,750 | 109,309 | 124.3 K to 109.3 K (-12.07 %) |
| Aug 07 2015 | AVM | AMAG PHARMACEUTICA ... | THOMAS FRANK E | President & COO | Buy | M | 14.91 | 15,000 | 223,650 | 124,309 | 109.3 K to 124.3 K (+13.72 %) |
| Aug 05 2015 | AVM | AMAG PHARMACEUTICA ... | HEIDEN WILLIAM K | CEO | Sell | S | 64.53 | 2,000 | 129,060 | 204,721 | 206.7 K to 204.7 K (-0.97 %) |
| Jul 17 2015 | AVM | AMAG PHARMACEUTICA ... | HEIDEN WILLIAM K | CEO | Option Exercise | M | 12.99 | 20,000 | 259,800 | 210,000 | |
| Jul 17 2015 | AVM | AMAG PHARMACEUTICA ... | HEIDEN WILLIAM K | CEO | Sell | S | 75.00 | 20,000 | 1,500,000 | 206,721 | 226.7 K to 206.7 K (-8.82 %) |
| Jul 17 2015 | AVM | AMAG PHARMACEUTICA ... | HEIDEN WILLIAM K | CEO | Buy | M | 12.99 | 20,000 | 259,800 | 226,721 | 206.7 K to 226.7 K (+9.67 %) |
| Jul 02 2015 | AVM | AMAG PHARMACEUTICA ... | HEIDEN WILLIAM K | CEO | Sell | S | 69.41 | 2,000 | 138,820 | 206,721 | 208.7 K to 206.7 K (-0.96 %) |
| Jun 17 2015 | AVM | AMAG PHARMACEUTICA ... | Holmes Scott A | SVP, Finance and Tr ... | Option Exercise | M | 16.55 | 3,500 | 57,925 | 11,500 | |
| Jun 17 2015 | AVM | AMAG PHARMACEUTICA ... | Holmes Scott A | SVP, Finance and Tr ... | Option Exercise | M | 14.89 | 2,734 | 40,709 | 14,375 | |
| Jun 17 2015 | AVM | AMAG PHARMACEUTICA ... | Holmes Scott A | SVP, Finance and Tr ... | Sell | S | 66.63 | 6,234 | 415,371 | 51,958 | 58.2 K to 52 K (-10.71 %) |
| Jun 17 2015 | AVM | AMAG PHARMACEUTICA ... | Holmes Scott A | SVP, Finance and Tr ... | Buy | M | 16.55 | 3,500 | 57,925 | 58,192 | 54.7 K to 58.2 K (+6.40 %) |
| Jun 17 2015 | AVM | AMAG PHARMACEUTICA ... | Holmes Scott A | SVP, Finance and Tr ... | Buy | M | 14.89 | 2,734 | 40,709 | 54,692 | 52 K to 54.7 K (+5.26 %) |
| Jun 17 2015 | AVM | AMAG PHARMACEUTICA ... | Holmes Scott A | SVP, Finance and Tr ... | Sell | S | 66.63 | 1,346 | 89,684 | 51,958 | 53.3 K to 52 K (-2.53 %) |
| Jun 08 2015 | AVM | AMAG PHARMACEUTICA ... | HEIDEN WILLIAM K | CEO | Option Exercise | M | 12.99 | 60,000 | 779,400 | 230,000 | |
| Jun 08 2015 | AVM | AMAG PHARMACEUTICA ... | HEIDEN WILLIAM K | CEO | Sell | S | 71.52 | 12,128 | 867,395 | 208,721 | 220.8 K to 208.7 K (-5.49 %) |
| Jun 08 2015 | AVM | AMAG PHARMACEUTICA ... | HEIDEN WILLIAM K | CEO | Sell | S | 70.69 | 4,680 | 330,829 | 220,849 | 225.5 K to 220.8 K (-2.08 %) |
| Jun 08 2015 | AVM | AMAG PHARMACEUTICA ... | HEIDEN WILLIAM K | CEO | Sell | S | 69.77 | 36,550 | 2,550,094 | 225,529 | 262.1 K to 225.5 K (-13.95 %) |
| Jun 08 2015 | AVM | AMAG PHARMACEUTICA ... | HEIDEN WILLIAM K | CEO | Sell | S | 68.90 | 6,642 | 457,634 | 262,079 | 268.7 K to 262.1 K (-2.47 %) |
| Jun 08 2015 | AVM | AMAG PHARMACEUTICA ... | HEIDEN WILLIAM K | CEO | Buy | M | 12.99 | 60,000 | 779,400 | 268,721 | 208.7 K to 268.7 K (+28.75 %) |
| Jun 08 2015 | AVM | AMAG PHARMACEUTICA ... | HEIDEN WILLIAM K | CEO | Sell | S | 68.14 | 6,875 | 468,463 | 208,721 | 215.6 K to 208.7 K (-3.19 %) |
| Jun 08 2015 | AVM | AMAG PHARMACEUTICA ... | THOMAS FRANK E | President & COO | Sell | S | 69.76 | 7,996 | 557,801 | 109,309 | 117.3 K to 109.3 K (-6.82 %) |
| Jun 08 2015 | AVM | AMAG PHARMACEUTICA ... | THOMAS FRANK E | President & COO | Sell | S | 69.27 | 12,004 | 831,517 | 117,305 | 129.3 K to 117.3 K (-9.28 %) |
| Jun 05 2015 | AVM | AMAG PHARMACEUTICA ... | Wilson Kenneth H | SVP, Sales and Mark ... | Sell | S | 68.77 | 5,388 | 370,533 | 25,000 | 30.4 K to 25 K (-17.73 %) |
| Jun 05 2015 | AVM | AMAG PHARMACEUTICA ... | Holmes Scott A | SVP, Finance and Tr ... | Sell | S | 68.88 | 22,516 | 1,550,902 | 30,788 | 53.3 K to 30.8 K (-42.24 %) |
| Jun 04 2015 | AVM | AMAG PHARMACEUTICA ... | HEIDEN WILLIAM K | CEO | Payment of Exercise | F | 67.77 | 11,378 | 771,087 | 215,596 | 227 K to 215.6 K (-5.01 %) |
| Jun 03 2015 | AVM | AMAG PHARMACEUTICA ... | Krop Julie | SVP Clinical & Regu ... | Option Exercise | A | 68.81 | 30,000 | 2,064,300 | 30,000 | |
| Jun 03 2015 | AVM | AMAG PHARMACEUTICA ... | Krop Julie | SVP Clinical & Regu ... | Grant | A | 0.00 | 22,000 | 0 | 22,000 | 0 to 22 K |